
Index

The abbreviations BA, MBA and DMBA have been used for benz[a]anthracene, methylbenz[a]anthracene and dimethyl-benz[a]anthracene respectively.

Abbreviations

- journal titles, xi—xiii
- other common, xiii—xiv

Absolute configuration

- and carcinogenic activity, 163—4
- differences, from metabolism, 90, 93—4, 96, 108—9
- fungal metabolism, 96
- of glutathione conjugate, 141

AcetoxyBA

- syntheses of, references to, 57—8

7-AcetoxyBA

- synthesis, 33, 46

7-Acetoxy-1,4-DMBA

- synthesis, 33

7-Acetoxy-9-methoxyBA

- synthesis, 33

7-Acetoxy-9-methoxy-1,4-DMBA

- synthesis, 33

7-AcetoxyethylBA

- direct mutagenic activity of, 151

7-AcetylBA

- synthesis from BA, 20

O-Acetylbenzoic acid

- use of in the synthesis of BA derivatives, 11

N-Acetyl-S-(5,6-dihydro-6-hydroxy-5-benzanthracenyl)-L-cysteine
urine metabolite of BA, 90

Adrenal apoplexy, 179

Adrenal gland

- activity of 7,12-DMBA metabolites in, 109—10
- cytochrome P-450 content of, 109
- 7,12-DMBA specific binding protein from, 142, 180
- effect of 7,12-DMBA in, 179—80
- metabolism of 7,12-DMBA in, 109—10

Adrenal necrosis

- active metabolite in, 179—80
- hormone dependence of, 179—80
- inhibition of, 179—80
- species dependence of, 107, 179—80
- relation to 7,12-DMBA metabolism, 107, 179—80
- suppression of, 109

Adrenal proteins

- 7,12-DMBA specific binding to, 142—3, 180

7-AldehydoBA

- synthesis of from BA, 20

212 *Index*

- 7-Aldehyde-11-MBA
 synthesis of from 11-MBA, 20
- Alkyl alcohols
 oxidation of, 88
- Alkylated BAs
 synthesis of from dimetallic intermediates, 19
- 7-AlkylBA
 effect of size on carcinogenicity, 166
- 8-AlkylBA
 effect of size on carcinogenicity, 166
- 7-Alkyl-12-MBA
 effect of size on carcinogenicity, 169
 synthesis of from Grignard reaction, 6
- Aflatoxin
 lack of mutagenic activity with mammary cells, 157
 metabolism of by mammary cells, 111
- Ames test, see under *Salmonella typhimurium*
- AminoBA
 carcinogenicity of, 168
 syntheses of, references to, 58
- 7-AminoBA
 synthesis from BA, 18—19
- 11-AminoBA
 synthesis of using Friedel-Crafts alkylation, 27—8
- Anthrasteriod rearrangement, 43—4
- Arene oxides
 synthesis of, 46
- Aromatic system of BA
 electron density of, 91
- ArylBA
 syntheses of, references to 52—3
- 5-ArylBA quinones
 synthesis of using photochemical cyclization, 35
- 7-ArylBA synthesis
 using Elbs reaction, 13
 using Grignard reaction, 42
- BA
 addition of oxygen to, 20
 binding of bovine serum albumin to, using light, 140
 carcinogenicity, 94—5, 160—1
 chemical reactivity, 18—20
 containing deuterium, tritium or ¹⁴C, 48
 contribution to mutagenicity of environmental samples, 145
 conversion into 7,12-DMBA by cytosolic proteins, 88, 95—6
 conversion into 7,12-DMBA using alkali metals, 9
 DNA binding of, 114—18
 enhanced carcinogenicity by alkyl substituents at particular positions, 84, 88, 164—5, 169
 faecal metabolite of, 90
 fluorescence spectrum of, relation to carcinogenicity, 83
 formation of by rearrangement of spiro compound, 22
 hepatic metabolism, effect of induction 92
 isotopically labelled, 47—8
 lack of promoting activity, 161
 malignant transformation of Syrian hamster embryo cells, 145
 metabolic formation of 7 and 12-alkylated BA from, 88, 95—6
 metabolism of, 90—6
 metabolism of in whole animals, 90—1
 mutagenicity of, 144—5
 protein binding, 140—2
 substituted at 7-position with various alkyl groups, carcinogenicity of, 166
 reaction with maleic anhydride, 20
 reaction with vinylene carbonate, 20
 reduction with lithium, 19
 RNA binding of, 114—18
 structure and numbering of, 1
 synthesis of, 46-7 syntheses of, references to, 49
 synthesis of using Dieckmann cyclization, 25—6
 synthesis of using Diels-Alder reaction, 37
 synthesis of using Friedel-Crafts alkylation, 27, 39—40
 synthesis of using Grignard reaction, 41
 synthesis of using Micheal addition, 23—4, 42
 synthesis of using Robinson-Mannich reaction, 23—4
 synthesis of radiolabelled C-5 and C-6, 43
 synthesis of using Wittig reaction, 42
 triangle of carcinogenicity of, 169
- BA acid
 syntheses of, references to, 60—1

Index

213

- BA adenine adduct, 116
- BA and substituted BAs
- carcinogenicity of, 160–86
 - DNA binding of, 113–40
 - metabolism of, 87–112
 - mutagenicity of, 144–59
 - protein binding of, 140–3
- BA bay region diol epoxide, 162–4
- carcinogenicity of isomers of, 163–4
 - differences in amounts of DNA adduct from, 117
- BA derivatives
- biological historical aspects of, 83–5
 - from benzenes and naphthalenes, 3–20
 - from condensation of cyclodehydration, 46–7
 - from decarboxylative alkylation, 45–6
 - from Dieckmann cyclization, 25–6
 - from Diels Alder reaction, 37–9
 - from dienone-phenol rearrangement, 24–5
 - from Elbs reaction, 13–4
 - from Friedel-Crafts reaction 21–2, 27–30
 - from Grignard reaction, 41
 - from Hayashi rearrangement, 14–18
 - from ketoacids, 3–9
 - from lithiated species, 44–5
 - from Michael reaction, 23–4, 42
 - from 1,4-naphthoquinones, 31–3
 - from organometallic intermediates, 9–13
 - from 1,4-phenanthraquinone, 30
 - from photochemical cyclization, 34–6
 - from Reformatsky reaction, 22–3
 - from Robinson-Mannich synthesis, 23–4
 - from Stobbe condensation, 38–9
 - from substituted furans, 33–4
 - from Vilsmeier reaction, 42
 - from Wagner-Meerwein and anthrasteroid reaction, 43–4
 - from Wittig reaction, 42
 - metabolism of, 85
 - protein interactions, 140–2
 - substituents, position of in relation to carcinogenicity, various structures of, 84
- BA 7,12-dialdehyde
- carcinogenicity, 183
- BA dihydrodiol, see also under dihydro dihydroxy BA
- carcinogenicity, 163
 - carcinogenicity of optical isomers of, 162–4
 - further metabolism of enantiomers of, 93–4
 - glutathione and, 141
 - K-region enantiomers, 108
 - metabolic formation of, 93
 - metabolic formation of *bis*-dihydrodiols, 94
 - mutagenicity, 145–8
 - optical isomers of, 93–4
- BA 3,4-dihydrodiol, see *trans*-3,4-dihydro-3,4-dihydroxy-BA
- BA diol epoxide, see also dihydro dihydroxy BA epoxide
- carcinogenicity, 162–4
 - carcinogenicity of optical isomers of, 162–4
 - comparison of biological activity of, 116
 - direct mutagenic activity of, 145–7
 - DNA adducts and, 115–18
- BA 3,4-diol 1,2-epoxide, see *trans*-3,4-dihydro-3,4-dihydroxy-BA 1,2-epoxide
- BA-7,12-dione, see BA quinone
- BA DNA adducts
- fluorescence spectra of, 115
 - in hamster embryo cells, 115–18
 - in mouse skin, 115–18
 - involvement of *trans*-3,4-dihydro-3,4-dihydroxy BA 1,2-epoxide in, 116–18
 - involvement of *trans*-8,9-dihydro-8,9-dihydroxy-BA 10,11-epoxide in, 115
 - using rat liver preparations, 115–18
- BA 5,6-epoxide
- absolute configuration of glutathione conjugate of, 141
 - carcinogenicity, 161
 - metabolic formation of dihydrodiols, phenols and glucuronide conjugates from, 91
 - mutagenicity of, 145
- BA guanine adduct, 115–16
- BA K-region epoxide, see under BA 5,6-epoxide
- BA lactone
- syntheses of, references to, 60–1
- BA metabolites
- carcinogenicity, 161–4
 - mutagenicity and inhibition of, 145–8

214 *Index*

- BA nucleus
 effect of substituents on
 carcinogenicity, 84, 164—6, 169—72
 effect of substituents on the sites of
 metabolism of, 99
- BA phenols
 DNA binding of, 117
- BA quinone, 14—18
 effect of various acids on preparation
 of, 14—5
 from metabolism, 94
 from oxidizing agents, 20
 reaction with Grignard reagent, 6
 synthesis of, 20
 synthesis of from Diels-Alder reaction,
 30
 synthesis of from keto acids, 3
 synthesis of from lithiated species,
 44—5
 synthesis of from Michal reaction, 24
- BA RNA adducts
 involvement of non-bay region
 dihydrodiol, 115—16
- BA structure-carcinogenicity relationship,
 83
- Bay region diol epoxide and epoxide, 85
 carcinogenicity, 162—4
 definition of, 87
 isomers of, 162—4
 involvement as ultimate carcinogen,
 167
 mutagenic activity, 145—7
- Bay region theory, 92—3
- Benz[a]anthrones, 9
- Benzo[a]pyrene, 111, 142, 143, 157
- Benzo[e]pyrene, 103
- Benzoflavone, 126—7, 181
- Benzoyloxymethyl-12-MBA
 carcinogenicity, 182—3
- 2-Benzylfurans, 33
- 7,12-*bis*-hydroxymethyl-7,12-dihydroBA
 synthesis of, 11
- Blocking of sites of metabolic activation,
 177
- Bovine serum albumin
 BA and derivatives binding to, 141
- Brominated BA
 syntheses of, references to, 53
- 7-BromoBA
 metabolites from, 99
 synthesis, 18—19
- 4-Bromo-7-BromomethylBA
 carcinogenic activity of, 182
- 2-Bromo-7,12-DMBA
 synthesis, 13
- 3-Bromo-7,12-DMBA
 synthesis, 13
- 8-Bromo-7,12-DMBA
 neurosarcomas by, 185
- 5-Bromo-12-MBA
 synthesis, 9
- 7-BromomethylBA
 carcinogenicity, 180
 DNA adducts of, 120—1, 139
 promoter activity of, 168
 transforming activity of, 151
- 7-Bromomethyl-12-MBA
 carcinogenicity, 139, 180—3
 DNA adducts of, 139—40
 X-ray crystallography of adduct, 140
- Butylated hydroxytoluene, 126—7
- Carbohydrates and 7,12-DMBA induced
 mammary cancer, 175—6
- Carboxaldehyde
 syntheses of, references to, 60
- CarboxyBA
 carcinogenicity, 169
 synthesis, 9—11, 20
- Carcinogenicity
 and absolute configuration, 164
 and metabolism, 99, 102—3
 and mutagenicity, 152—3
 and mitochondrial DNA, 117
 bay region epoxide and, 92—3
 DNA and, 113—14, 139—40
 factors affecting, 85, 142
 Iball index, 160
 inhibition, 174, 175, 177
 introduction to, 160
 of BA, 160—1
 of BA metabolites, 161—4
 of disubstituted BAs, 169—83
 of monosubstituted BAs, 164—9
 of tetrasubstituted BAs, 186
 of trisubstituted BAs, 183—5
 molecular thickness, relation to, 169—72
 steps in, 113—14, 173—4
- Catechol group, 141
- ¹⁴C-BA, 43, 47—8
- Chartreusin aglycone, 32—3
- Chinese hamster V79 cells, 121, 145—6,
 149—50, 152, 154—8

- Chlorinated BA, 18—19
 syntheses of, references to, 54
- 4-Chloro-7-bromomethylBA
 carcinogenicity, 182
- 4-Chloro-1-hydroxy-5-
 synthesis, 15
- 7-ChloromethylBA
 carcinogenicity, 168
 synthesis, 19
- 7-chloromethyl-12-MBA
 carcinogenicity, 180—1
 synthesis, 7
- Coal tar and carcinogenicity, 83
- Configuration and carcinogenicity, 163—4
- Conformation
 alteration of by substituents, 99, 181
 effect on HPLC retention time of
 dihydrodiol, 97
 effect on metabolism, 93
- Contents, v—vii
- Copper coordination compound
 and inhibition of mutagenicity, 152
- Cunninghamella elegans*, 96, 97
- CyanoBA, 18—19
 carcinogenicity, 185
 syntheses of, references to, 59
- Cyclisation, 38
 effect of steric factors, 41
- 5-CyclohexylBA quinone, 36
- Cytochrome P-450
 induction of, 87, 93—4, 105, 141—2
 introduction to, 87—8
 isoenzymes of, 87, 100
 location of, 87, 109
 metabolism by, 93, 106
 receptor protein for, 141—2
 stereoselective metabolism by, 90, 93—
 4
- Decarboxylative alkylation, 45—6
- Deoxyadenosine adduct, 123—4
- Deuterated BAs
 synthesis, 14
- 7,12-Dialdehyde-7,12-dihydroxyBA, 11
- DialkylBA
 size and carcinogenicity, 169—72
 syntheses of, references to, 51
- quasi*-Diaxial conformation, 89, 93, 97,
 99, 181
- Dibenz[a,h]anthracene, 83
- N⁶,O²-Dibutylcyclic adenosine 3',5'-
 monophosphate, 129
- 5,6-DicarboxyBA anhydride
 synthesis, 37
- Dieckmann reaction, 25—6
- Diels-Alder reaction, 30, 31—6, 37—9
- Dienone-phenol rearrangement, 24—5
quasi-Diequatorial conformation, 89, 98
- 6,7-DiethylBA, 172
- 7,12-DiethylBA
 carcinogenicity, 172
 synthesis, 6
- 7,12-DifluoroBA
 carcinogenicity, 181—2
 synthesis, 18—19
- 5,6-DihydroBA, 116—17
- 7,12-DihydroBA
 synthesis, 19, 37
- trans*-1,2-Dihydro-1,2-dihydroxyBA
 as a hepatic metabolite from BA, 91
 carcinogenicity, 162
 metabolism of optical isomers of, 93
- trans*-3,4-Dihydro-3,4-dihydroxyBA
 carcinogenicity, 161—4
 carcinogenicity, of optical isomers of,
 163
 metabolic formation of, 93—5
 metabolism of to a diol epoxide, 94—5
 mutagenicity, 145
 optical isomers of, 93—4
- trans*-5,6-Dihydro-5,6-dihydroxyBA
 as a hepatic metabolite from BA, 91
 carcinogenicity, 162
 synthesis, 18—19
- trans*-8,9-Dihydro-8,9-dihydroxyBA
 carcinogenicity, 162
 glutathione binding of, 141
 metabolic formation of, 90—1, 91—3
 metabolism of to a diol epoxide, 92,
 95
- trans*-10,11-Dihydro-10,11-dihydroxyBA
 carcinogenicity, 162
 metabolism of to a diol epoxide, 95
- trans*-3,4-Dihydro-3,4-dihydroxy-BA 1,2-
 epoxide
 carcinogenicity, 162—5
 carcinogenicity, of isomers of, 163—5
 definition of isomers of, 163
 mutagenicity of isomers of, 145—7
 reaction with DNA and RNA, 116
- trans*-8,9-Dihydro-8,9-dihydroxyBA 10,11-
 epoxide
 characterisation of guanine adduct of,
 115—16
 glutathione binding of, 141
 metabolic formation of, 95

216 *Index*

- mutagenicity, 148
- reaction with DNA and RNA, 95, 115—16
- single strand breaks in DNA by, 116
- trans*-10,11,-Dihydro-10,11-dihydroxyBA
 - 8,9-epoxide
 - DNA binding, lack of 95, 116
 - metabolic formation of, 95
- trans*-1,2-Dihydro-1,2-dihydroxy-7,12-DMBA
 - factors affecting metabolic formation of, 107
 - metabolic formation of in human skin, 102
- trans*-3,4-Dihydro-3,4-dihydroxy-7,12-DMBA
 - carcinogenicity, 177
 - DNA binding of, 131-2
 - metabolic formation of, 101—7
 - mutagenicity, 154—6
- trans*-5,6-Dihydro-5,6-dihydroxy-7,12-DMBA
 - carcinogenicity, 177—8
 - configuration of, 108
 - metabolic formation of, 101, 104—5, 108
 - Mutagenicity, 154—6
- trans*-8,9-Dihydro-8,9-dihydroxy-7,12-DMBA
 - carcinogenicity, 177—8
 - metabolic formation of, 101—4, 106, 110
 - mutagenicity, 154—6
- trans*-10,11-Dihydro-10,11-dihydroxy-7,12-DMBA
 - carcinogenicity, 177
 - metabolic formation of, 101, 104
 - mutagenicity, 154—6
- trans*-8,9-Dihydro-8,9-dihydroxy-7,12-DMBA 10,11-epoxide
 - carcinogenicity, 177—8
- trans*-3,4-Dihydro-3,4-dihydroxy-7-fluoroBA
 - high mutagenic activity of, 151
 - metabolic formation of, 99
- trans*-3,4-Dihydro-3,4-dihydroxy-12-hydroxymethyl-7-MBA
 - carcinogenicity, 179
- trans*-1,2-Dihydro-1,2-dihydroxy-7-MBA
 - carcinogenicity, 167
 - metabolic formation of, 97
- trans*-3,4-Dihydro-3,4-dihydroxy-7-MBA,
 - carcinogenicity, 167
 - metabolic formation of, 97
 - mutagenic activity of, 149—50
- trans*-3,4-Dihydro-3,4-dihydroxy-8-MBA
 - carcinogenicity, 167
- trans*-5,6-Dihydro-5,6-dihydroxy-7-MBA
 - carcinogenicity, 167
 - metabolic formation of, 97—8
 - mutagenicity, 149—51
- trans*-8,9-Dihydro-8,9-dihydroxy-7-MBA
 - carcinogenicity, 167
 - metabolic formation of, 97
 - mutagenicity, 149—51
- trans*-10,11-Dihydro-10,11-dihydroxy-7-MBA
 - metabolic formation of, 97—8
- trans*-3,4-Dihydro-3,4-dihydroxy-7-MBA 1,2-epoxide
 - carcinogenicity, 167
- trans*-Dihydrodiol
 - conformation of, effect on diol epoxide formation, 89, 90
 - effects of *peri* substituents on, 181
 - differences in cellular location of, 102
 - metabolism of, 90, 93—5
 - optical isomers of, 93, 97—8
 - precursor to bay region diol epoxide, mutagenicity, 152—3
- Dihydrodiol dehydrogenase, 141, 148
- 1,2-Dihydro-7,12-DMBA
 - mutagenic activity, 154—6
- 7,12-Dihydro-7,12-DMBA
 - isomers of, 19
 - synthesis of, 9
- 5,6-Dihydro-6-fluoro-5-keto-7,12-DMBA
 - synthesis, 19
- S-5,6-Dihydro-(6-hydroxy-7-methyl-5-BA) glutathione
 - metabolic formation of from 7-MBA, 97
- 5,6-Dihydro-1-MBA quinone, 45
- cis*-7,12-Dihydroxy-7,12-DMBA
 - metabolic formation of, 108
- 7,12-DihydroxymethylBA
 - carcinogenicity, 179
 - metabolic formation of by cytosolic proteins, 105
 - metabolism, 103—4, 107
 - mutagenicity of 3,4-dihydrodiols of, 156
- DihydroxymethylBA quinones
 - synthesis, 46
- 5,12-Dihydroxy-6-phenylBA
 - synthesis, 47

- 5,6-DiketoBA
 synthesis, 20
- 5,6-Diketo-7,12-DMBA
 synthesis, 20
- 3,9-DimethoxyBA
 synthesis, 38
- 7,12-DimethoxyBA
 carcinogenicity, 183
- 1,3-Dimethylisobenzofuran, 33
- Diol epoxide
 and carcinogenicity, 85
 definition of *syn* and *anti* isomers of
 89, 93—4, alternate definition,
 162—3
 derivatives of, 88
 DNA binding of, 116, 117—18, 133—
 5
 formation of, 87
 interaction with phenylboronic acid,
 133—4
 optical isomers of, 89
 structure, 89
 requirement in metabolic activation, 92
- Direct alkylation of DNA and
 carcinogenicity, 180—1
- Disubstituted BA
 carcinogenicity, 169
 DNA binding, 122—40
 metabolism, 101—11
 mutagenicity, 152—7
- DMBA
 carcinogenicity, of structural isomers
 of, 169—72
 syntheses of, references to, 50—1
- 1,6-DMBA
 synthesis, 23—4, 40—1
- 1,7-DMBA
 carcinogenicity, 171
- 1,12-DMBA
 carcinogenicity, 171
 description of melting point, 38
 difficulties in synthesis of, 38—9
 physical characteristics of, 39
 resemblance to benzo[a]pyrene of, 37—
 8
 synthesis, 38—9
- 2,6-DMBA
 synthesis, 40—1
- 2,9-DMBA
 carcinogenicity, 171
 synthesis, 13
- 2,10-DMBA
 carcinogenicity, 171
 synthesis, 13
- 3,4-DMBA
 synthesis, 22
- 3,6-DMBA
 synthesis, 40—1
- 3,9-DMBA
 carcinogenicity, 171
 synthesis, 13
- 3,10-DMBA
 carcinogenicity, 171
 synthesis, 13
- 4,7-DMBA
 carcinogenicity, 171
 synthesis, 43—4
- 4,12-DMBA
 carcinogenicity, 171
- 5,7-DMBA
 synthesis, 38
- 5,12-DMBA
 carcinogenicity, 171
- 6,7-DMBA
 carcinogenicity, 171
- 6,8-DMBA
 carcinogenicity, 171
 synthesis, 9
- 6,12-DMBA
 carcinogenicity, 171
- 7,8-DMBA
 carcinogenicity, 171
 synthesis, 6
- 7,11-DMBA
 carcinogenicity, 171
 synthesis, 28
- 7,12-DMBA, *see also* under 7,12-DMBA
 specific topics
 absorption from application site, 101
 activation routes not involving bay
 region, evidence for, 154—6, 178—
 9
 addition of oxygen to, 20
 adrenal cortex, effect on, 178—80
 application to hamster cheek pouch,
 174
 application to skin, 101, 172—4
 application to skin, human, 172
 as a mammary carcinogen, 174—6
 as a skin carcinogen, 172—4
 binding to adrenal proteins, 142
 excretion of after topical application to
 mouse skin, 172
 hydroxymethylsulphate ester of, 109
 immunization against cancer with, 174
 immunotoxicity, 179

218 *Index*

- metabolic formation of, 88, 95—6, 98, 100—1
- protein binding, 142—3
- synthesis, 6—7, 9, 11, 20, 33
- synthesis of, difficulties in, 6
- synthesis of, improvements in, 6—9
- testes, effect on, 180
- 8,9-DMBA
 - carcinogenicity, 171
 - synthesis, 27
- 8,10-DMBA
 - synthesis, 29
- 8,11-DMBA,
 - carcinogenicity, 171
 - synthesis, 28
- 8,12-DMBA
 - carcinogenicity, 171
 - synthesis, 5
- 9,11-DMBA
 - synthesis, 29-30
- 7,12-DMBA carcinogenicity, 84, 172—80
 - dietary constituents and, 176
 - enhancement in, 177—8, 185
 - hormone dependence, 142—3, 176
 - initiation of, 142
 - induction of cancer in offspring, 176
 - induction of leukaemia, 176
 - induction of mammary cancer, 174—6
 - induction of melanomas in hamster, 176
 - induction of skin cancer, 142
 - induction of transplacental carcinogenicity, 176
 - induction of tumours by intravaginal administration, 174
 - inhibition of, 176
 - of mammary tissue, resemblance to human mammary cancer, 175
 - involving the aliphatic groups, 179
 - involving the aromatic nucleus, 177—9
 - mode of application dependence, 172
 - reduction of, 175, 177—9, 182
 - tissue independence of, 176
- 7,12-DMBA derivatives
 - as complete carcinogens, 178—9
- 7,12-DMBA derivatives containing halogen
 - carcinogenicity, 178, 180—2, 185
 - rat liver metabolism of, 112
- 7,12-DMBA derivatives containing methoxy group
 - carcinogenicity, 178, 185
- 7,12-DMBA derivatives containing phenol group
 - carcinogenicity, 177—8, 182, 185
 - mutagenicity of, 154, 158
- 7,12-DMBA dihydrodiols, see also individual dihydro dihydroxy entries
 - carcinogenicity, 177
 - DNA binding, 122—40
 - metabolic formation, 107
 - mutagenicity, 154—6
- 7,12-DMBA diol epoxides
 - characterization of bay region DNA adducts of, 123, 134
- 7,12-DMBA DNA binding, 122—37
 - adducts in hamster embryo cells, 136—7
 - adducts in hepatoma cells, 137
 - adducts in human embryo cells, 137
 - adducts in mammary tissue, 127—30
 - adducts in mouse embryo cells, 132—4, 136
 - adducts in mouse skin, 122—7
 - adducts in rat liver, 130—2
 - and carcinogenicity, 122
 - bay region diol epoxide involvement in, 123, 131—3
 - by routes other than a bay region diol epoxide, 138
 - characterization of adducts, 123—8, 131—8
 - comparison between different tissues, 131, 136
 - comparison between species of, 136
 - comparison with that of benzo[a]pyrene, 134—5
 - concentration effects on, 131
 - dihydrodiol metabolites and, 131—3
 - effect of hydroxylation of methyl groups on, 126
 - effect of various substituents on, 126
 - fluorescence spectra of adducts, 122—3, 132—3
 - inhibitors of mouse skin
 - carcinogenicity, effects on, 126—7
 - K-region epoxide involvement in, 131, 137—8
 - persistence of adducts in mouse skin, 124—5
 - phenylboronic acid interaction with adducts by, 133—4
 - stability of adducts, 114, 136
 - repair of adducts, 128—9
 - repair of adducts, lack of, 136

Index

219

- 7,12-DMBA 5,6-epoxide
 absolute configuration, 108—9
 carcinogenicity, 177
 DNA adducts, 131, 137—8
 metabolic formation of, 108—9
 metabolism of, 107
 mutagenicity, 154
 synthesis, 107
- 7,12-DMBA metabolism, 101—11
 and adrenal necrosis, 107
 and excretion after application to mouse skin, 172
 and genetic background, 110—11
 and physiological state, 110—11
 by purified cytochrome P-450 isoenzymes, 105—6
 comparison of in hamster embryo and human hepatoma cells, 102—3
 comparison of, in hepatic nuclei and microsomes, 105
 comparison of, in human, mouse and rat skin, 101—2
 dihydrodiol formation from, 101—11
 dihydrodiol, inhibition of further metabolism of, 103
 effect of liver enzyme inducers on, 105—6
 factors affecting, 105—6
 glucuronic acid conjugate, 102
 in adrenal gland, 109—10
 in embryo cells, hamster, 102—3
 in embryo cells, mouse, 102
 in epidermal cells, hamster, 102
 in epidermal cells, mouse, 102
 in hepatoma cells, human, 103
 in liver, hamster, 105
 in liver, rat, 103—9
 in lung, mouse, 103
 in macrophages, mouse, 103
 in mammary gland, 110—11
 in rats, 101
 in skin, mouse, 101—2
 lack of 3,4-dihydrodiol in human skin, 102
 production of faecal metabolite, in mouse, 101
 production of faecal metabolite, in rat, 101
- 7,12-DMBA mutagenicity, 152, 156—7
 and malignant transformation, 152, 154—6
 comparison with other carcinogens, 153
 inhibition of, 152—3
 lack of correlation with
 carcinogenicity, 152—3
 mammary cell mediated, 156—7
 from metabolites, 154—6
- 7,12-DMBA protein binding, 142—3
 adrenal proteins and, 142
 effect of light on, 142
 effect of on steroid binding to receptor proteins in mammary gland, 142—3
 specificity for, 143
 nuclear proteins and, 143
- 7,12-DMBA RNA binding, 138
- DNA
 adducts and carcinogenicity, 139—40
 BA derivatives binding to, 114—18
 BA disubstituted derivatives binding to, 122—40
 BA monosubstituted derivatives binding to, 118—22
 BA trisubstituted derivatives binding to, 140
 nuclear or mitochondrial, BA binding to, 117
 repair, 121, 128—9
 single strand breaks of, 116
 tissue from differences in, 117, 130
- DNA, RNA and protein interactions with BA derivatives, 113—43
- Double bonds, of BA
 susceptibility to metabolic attack, differences in, 91
- Drosophila melanogaster*
 BA mutagenicity in, 145
 7,12-DMBA mutagenicity in, 152
- Elbs reaction, 13—14
- Electronic effects, 112, 181
 influence on metabolism by, 112
- Electrophile, 113
- Enantiomers
 and carcinogenicity, 163—4
 factors affecting composition, 108
 of *trans*-dihydrodiols, 89, 93
- 7,12-Epideoxy-7,12-DMBA, 20
- Epigenetic changes, 113
- Epoxide, see also diol epoxide
 enantiomers of, 108
 metabolic formation of, 91—2
 reactions of, 88
 requirement of for carcinogenicity, 85
- Epoxide hydrolase, 87, 93

220 *Index*

- Ergosterol
 conversion into 4,7-DMBA, 43—4
- 7-Ethoxymethyl-12-MBA
 carcinogenicity, 183
- 7-EthylBA
 synthesis, 9—11
- 11-EthylBA
 synthesis, 27—8
- 4-Ethyl-3-MBA
 synthesis, 22
- Fat, dietary and mammary cancer, 175—6
- Fluorescence
 of BA DNA adducts, 115
 of 7,12-DMBA DNA adducts, 122—3,
 132—3
 of 7-MBA DNA adducts, 119—20
 of 12-MBA DNA adducts, 122
- Fluorine
 as a substituent, effect on
 conformation, 181
 as a substituent, effect on metabolism,
 102—3, 112, 181
 enhancement in carcinogenicity, by,
 168, 177—8
 resonance effects and carcinogenicity,
 181, 185
 toxic derivatives, 181
- Fluorinated BA
 syntheses of, references to, 54—5
- 1-FluoroBA
 synthesis, 9
- 3-FluoroBA
 carcinogenicity, 168
- 4-FluoroBA
 carcinogenicity, 168, 181
 toxicity of, 168, 181
- 5-FluoroBA
 reaction with vinylene carbonate, 20
 synthesis, 9
- 6-FluoroBA
 metabolism of, 96
- 7-FluoroBA
 carcinogenicity, 168
 configuration and conformation of
 dihydrodiol of, 99
 metabolism of, 99
 mutagenicity of, 151
 synthesis, 18—19, 34—5
- 8-FluoroBA
 synthesis, 14
- 12-FluoroBA
 carcinogenicity, 168
- 6-Fluoro-7-BromomethylBA
 carcinogenicity, 182
- 1-Fluoro-7,12-DMBA
 carcinogenicity, lack of, 177—8, 185
 mutagenicity of, 157—8
- 2-Fluoro-7,12-DMBA
 carcinogenicity, lack of, 177—8, 185
 DNA adducts of, 129—30
 metabolism of, 102—3, 112
 mutagenicity of, 157—8
- 3-Fluoro-7,12-DMBA
 metabolism of, 112
- 4-Fluoro-7,12-DMBA
 carcinogenicity, 177—8, 185
 metabolism of, 112
 synthesis, 9
- 5-Fluoro-6,8-DMBA
 synthesis, 9
- 5-Fluoro-7,12-DMBA
 carcinogenicity, lack of, 177—8, 185
 DNA binding of, 137, 140
 metabolism of, 102—3, 112
 mutagenicity of, 157—8
 synthesis, 11, 20
- 8-Fluoro-7,12-DMBA
 synthesis, 9
- 9-Fluoro-7,12-DMBA
 carcinogenicity, 177, 185
- 10-Fluoro-7,12-DMBA
 carcinogenicity, high of, 177—8, 185
 DNA binding, 126
 mutagenicity, 158
- 11-Fluoro-7,12-DMBA
 carcinogenicity, 177—8, 185
 mutagenicity, 157—8
- 5-Fluoro-7-hydroxymethyl-12-MBA
 carcinogenicity, 185
 DNA binding of, and of acetate ester of,
 140
- 1-Fluoro-7-MBA
 synthesis, 9
- 2-Fluoro-7-MBA
 carcinogenicity, 181
- 3-Fluoro-7-MBA
 carcinogenicity, 181
 metabolism, 101
- 4-Fluoro-7-MBA
 difficulties in testing carcinogenicity,
 of, 181
 high toxicity of, 181
- 5-Fluoro-7-MBA
 carcinogenicity, lack of, 181

- discussion of lack of carcinogenicity, 181
- metabolism of, 101
- 6-Fluoro-7-MBA
 - carcinogenicity, 181
- 6-Fluoro-12-MBA
 - metabolism of, 101
- 7-Fluoro-7-MBA
 - carcinogenicity, 181—2
- 7-Fluoro-12-MBA
 - synthesis, 19
- 8-Fluoro-7-MBA
 - synthesis, 9
- 9-Fluoro-7-MBA
 - carcinogenicity, 181
- 10-Fluoro-7-MBA
 - carcinogenicity, 181
- 12-Fluoro-7-MBA
 - carcinogenicity, 181—2
 - synthesis, 19, 34—5
- 8-Fluoro-3-methylcholanthrene
 - synthesis, 13—14
- 10-Fluoro-3-methylcholanthrene
 - synthesis, 13—14
- 11-Fluoro-3-methylcholanthrene
 - synthesis, lack of, 14
- 12-Fluoro-3-methylcholanthrene
 - synthesis, lack of, 14
- Formic acid, 9
- 7-Formyl BA
 - carcinogenicity, 169
- 7-Formyl-11-MBA
 - synthesis, 28
- 7-Formyl-12-MBA
 - carcinogenicity, 182—3
- Friedel-Crafts alkylation, 21—2, 27—30, 29, 39—41
- Fungal metabolism of BA derivatives, 96, 97
- Furans, use of and limitations in BA derivative synthesis, 33—4
- Genetic background and metabolism by mammary gland, 110—11
- Glucuronic acid conjugates, 90, 95
- Glutathione, 88, 95, 97, 141, 142
- Glutathione-S-transferases, 88, 141
- Grignard reaction, 3—4, 6, 41—2
- Halogen BA
 - carcinogenicity, 168
 - mutagenicity, 151
 - metabolism, 99
- Halogen BA quinones
 - synthesis, 31
- HalogenmethylBA
 - carcinogenicity, 168
 - DNA binding, 120—1
 - mutagenicity, 151
 - syntheses of, references to, 59
- Hamster
 - carcinogenicity in, lack of, 102
 - cheek pouch carcinogenicity, 174
- Hamster embryo cells, 143
 - DNA and RNA adducts in, 115—19, 123, 136—7, 140—1
 - metabolism in, 95, 102, 103
 - mutagenicity, 145—59
- Hamster epidermal cells, 102
- Hayashi rearrangement, 5, 14—18
- Hepatoma cell line, human, 136—7, 158
- 1,2,3,4,7,12-HexahydroBA, 19
- Hindered and unhindered acids, definition, 3
- Histones and 7,12-DMBA binding to, 143
- Hormones and mammary cancer 142—3, 175
- HPLC
 - effect of conformation of *trans*-dihydrodiol on retention time, 98
- Human embryo and tumour cells
 - 7,12-DMBA DNA binding in, 137
- Human hepatoma cells, 103, 158
- Human lymphocytes, 121
- Human skin
 - treatment of with 7,12-DMBA, 172
- Hydroxy BA
 - carcinogenicity, 168
 - syntheses of, references to, 56—7
- 2-HydroxyBA
 - synthesis, 46
- 3-HydroxyBA
 - as hepatic metabolite from BA, 90—1
- 4-HydroxyBA
 - as hepatic metabolite from BA, 91
 - excretion in faeces, 90
 - synthesis, 22
- 5-HydroxyBA
 - carcinogenicity, 168
- 7-HydroxyBA
 - carcinogenicity, 168
 - 11-HydroxyBA
 - carcinogenicity, 168
 - synthesis, 27—8
- 12-HydroxyBA
 - synthesis, 47
- 1-HydroxyBA quinone

222 *Index*

- synthesis, 45
- 3-HydroxyBA quinone
 - synthesis, 45
- 4-Hydroxy-7,12-DMBA
 - as faecal metabolite, 101
- 11-Hydroxy-1-methoxy-4-MBA quinone
 - synthesis, 32
- Hydroxyl group, 87—8
- HydroxymethylBA
 - effect of hydroxylation on
 - carcinogenicity, 107, 179
 - metabolic formation of, 96—100
 - mutagenic activity, 154—6
 - syntheses of, references to, 60
- 7-HydroxymethylBA
 - adrenal activity, lack of, 109—10
 - carcinogenicity, 166—7
 - DNA binding of, 121—2
 - mutagenicity of, 151
 - promoting activity, lack of, 168
- 8-HydroxymethylBA
 - carcinogenicity, 167
- Hydroxymethyl-7,12-DMBA derivatives
 - and mammary cancer, 175
- 2-Hydroxy-4-methyl-5,6,8,9, 10, 11-hexahydr BA
 - synthesis, 24—5
- 7-Hydroxymethyl-12-MBA
 - adrenal activity, 109—10, 180
 - carcinogenicity, 182—3
 - carcinogenicity of 3,4-dihydrodiol of, 179
 - DNA adducts, 131, 132—3, 135—6, 138—40
 - metabolic formation of, 103—5, 107
 - metabolism, 103—4, 107
 - mutagenicity of 3,4-dihydrodiol of, 156
- 12-Hydroxymethyl-7-MBA
 - adrenal activity, lack of, 109—10
 - carcinogenicity, 179
 - carcinogenicity of 3,4-dihydrodiol of, 179
 - DNA adducts of, 132—3
 - metabolic formation of, 103—5, 107
 - metabolism of, 103—4, 107
 - mutagenicity, 156
 - mutagenicity of 3,4-dihydrodiol of, 156
- 7-Hydroxymethylsulphate-12-MBA
 - metabolic formation of by rat liver cytosol, 109
 - mutagenicity, 109
- 7-Idomethyl-12-MBA
 - carcinogenicity, 180—1, 182—3
 - synthesis, 6—7
- 5,6-IminoBA
 - synthesis, 19
- 5,6-Imino-7,12-DMBA
 - synthesis, 19
- Immunization against 7,12-DMBA induced cancer, 174
- Inhibition
 - of BA metabolism, 93
 - of 7,12-DMBA induced mammary cancer, 129—30, 176
 - of mutagenicity by plant flavanoids, 146—8
 - of skin cancer, 174
- Initiation, and promotion, 85, 173
- Isolated double bond, and lack of metabolism, at, 94, 96—7
- 5-IsopropylBA
 - synthesis, 13
- Isotopically labelled BA, 43, 47—8
 - synthesis of, references to, 61
- Ketoacids
 - hindered and unhindered, conversion of, 16
 - hindered and unhindered, definition, 3
 - separation of, 4—5
 - synthesis, 3—5, 21—2, 28
 - use of in the synthesis of BA derivatives, 3—9
- 8-Keto-1,2,3,4,5,6,8,9,10,11-dodecahydro BA
 - synthesis, 29
- 4-Keto-1,2,3,4,5,6-hexahydro BA
 - synthesis, 25—6
- 11-Keto-5,6,8,9,10,11-hexahydroBA, use of 27—8
- 4-Keto-1,2,3,4-tetrahydro BA
 - synthesis, 33
- 8-Keto-8,9,10,11-tetrahydroBA
 - synthesis, 27
- 8-Keto-8,9,10,11-tetrahydro-10-MBA
 - synthesis, 29
- K-region
 - absolute configuration of glutathione conjugate of, 141
 - and DNA binding, 119
 - trans*-dihydrodiol, enantiomeric composition, 97—8, 100, 108
 - dihydrodiol metabolite, 90, 97, 99, 105—6
- Iball index, 160

- effect of methyl group on stereochemistry of, 100
 electron density of, 91
 epoxide, carcinogenicity, 161, 167
 epoxide, enantiomeric composition of, 96, 98, 100, 108—9
 epoxide, metabolic formation of, 90—1
 epoxide, metabolism of, 91
 mercapturic acid metabolite of, 90—1
 mutagenicity, 145, 149—51
- Lactation, and reduction in mammary cancer, 175
- Leukaemia, induction by 7,12-DMBA, 172, 176
- Light
 activation of PAH to mutagen by, 151
 binding of PAH to protein by, 140, 142
- O*-Lithiated 2-aryl-4,4-dimethyl-2-oxazolines, 12—13
- Lithiated species, reactions of, 44—5
- 7-LithioBA
 synthesis, 9—11
- Liver
 and metabolism, 91—101, 103—9
 DNA adducts in, 130—2
 induction of cytochrome P-450 enzymes in, 87, 93—4, 105—6, 108—9
 stereochemistry of metabolites of, 90, 93, 97—8, 108
- Long Evans rat, 129, 157
- Lung, metabolism in, 103
- Macrophages, 103
- Malignant transformation, 144
 of mouse fibroblasts, 150, 152, 154—6
 of mouse prostate cells, 152
 of Syrian hamster embryo cells, 145, 151
- Mammary gland
 activation of oncogene in, 128
 cancer and dietary constituents, 175—6
 cancer, and DNA synthesis, 130
 cancer, 7,12-DMBA induced, 174—6
 cancer, effect of lactation, 175
 cancer, effect of pregnancy on, 175
 cancer, hormone dependence on, 142—3, 175
 cancer, inhibition of, 175—6
 cancer, inhibition of in relation to 7,12-DMBA adducts, 129
 cancer, metabolites of 7,12-DMBA, 175
- cancer, mice, 175
 cancer, rat resemblance to human mammary cancer, 175
 7,12-DMBA DNA adducts in, 127—30
 epithelial cells, DNA adducts in, 130
 fibroblast cells, DNA adducts in, 130
 metabolism by, 110—11, 130
 mutagenicity, 156—7
 proteins and 7,12-DMBA binding, 142
 proteins and steroid binding, 142—3
 repair of DNA in, 128—9
- MBAs
 carcinogenicity, 84, 164—7
 effect of position of methyl group on carcinogenicity of, 164—6
 metabolites, mutagenicity of, 149—51
 mutagenicity of, 148—9
 syntheses of, references to, 49
- 1-MBA
 carcinogenicity, 164—6
 K-region epoxide, enantiomeric composition of, 96
 metabolism, 96
 mutagenicity, 148—9
 synthesis, 21—2, 23—4
- 2-MBA
 carcinogenicity, 164—6
 mutagenicity, 148—9
 synthesis, 13, 27, 39—40, 41, 46
- 3-MBA
 carcinogenicity, 164—6
 mutagenicity, 148—9
 synthesis, 13, 38, 41
- 4-MBA
 carcinogenicity, 164—6
 fungal metabolism of, 97
 mutagenicity, 148—9
 stereoisomers from fungal metabolism, 97
 synthesis, 22—3, 24—6, 41
- 5-MBA
 carcinogenicity, 164—6
 mutagenicity, 148—9
 synthesis of containing ¹⁴C, 43
- 6-MBA
 carcinogenicity, 164—6
 metabolism of, 96—7
 metabolites, mutagenicity of, 149
 mutagenicity, 148—9

224 *Index*

- oxidative metabolism at C-6, 96
- synthesis, 23—4, 29, 40—1
- synthesis of containing ¹⁴C, 43
- 7-MBA
 - addition of oxygen to, 20
 - carcinogenicity, 84, 164—6
 - carcinogenicity of metabolites of, 166—7
 - dihydrodiols, 97—8
 - dihydrodiols, conformation of effect on HPLC retention time, 97
 - glutathione conjugate, 97
 - metabolic formation of, 88, 95—6
 - metabolism, 97—8
 - metabolism to 7,12-DMBA, 98
 - metabolites, carcinogenicity of, 166—7
- metabolites, DNA binding of, 118—20
- methyl group hydroxylation, 98
- mutagenicity, 148—9
- mutagenicity, of metabolites, 149—51
- stereoisomers of dihydrodiols, 97—8
- synthesis, 5—6, 9—11
- synthesis, metabolic, 88, 95—6
- 8-MBA
 - carcinogenicity, 164—6
 - enantiomeric composition of metabolites, 99—100
 - metabolism, 99—100
 - metabolites, carcinogenicity of, 166—7
 - mutagenicity, 148—9
 - oxidative metabolism at C-8, 100
 - synthesis, 30, 38
- 9-MBA
 - carcinogenicity, 164—6
 - mutagenicity, 148—9
 - synthesis, 13, 27, 38
- 10-MBA
 - carcinogenicity, 164—6
 - mutagenicity, 148—9
 - synthesis, 28—9
- 11-MBA
 - carcinogenicity, 164—6
 - enantiomeric composition of metabolites, 100
 - metabolism, 100
 - mutagenicity, 148—9
 - oxidative metabolism at C-11, 100
 - synthesis, 27—8, 30, 38
- 12-MBA
 - carcinogenicity, 164—6
 - enantiomeric composition of metabolite, 100
 - metabolic formation of 7,12-DMBA, 100—1
 - metabolism, 100
 - metabolites, DNA binding of, 122
 - methyl group hydroxylation, 100—1
 - mutagenicity, 148—9
 - synthesis, 5
- 7-MBA-12-aldehyde
 - carcinogenicity, 183
- 12-MBA-7-aldehyde
 - carcinogenicity, 183
- MBA cyano derivatives
 - carcinogenicity, 182
- 4-MBA dihydrodiols
 - from fungal metabolism, 96
 - metabolic formation of, 96
 - stereoisomers of, 96
- 6-MBA dihydrodiols
 - metabolic formation of, 96—7
 - mutagenicity, 149
- 7-MBA dihydrodiols, see also under individual dihydro dihydroxy
 - carcinogenicity, 167
 - metabolic formation of, 97—8
 - mutagenicity, 149—50
- 8-MBA dihydrodiols
 - carcinogenicity, 167
 - metabolic formation of, 99—100
- 11-MBA dihydrodiols
 - metabolic formation of, 100
- 12-MBA dihydrodiols
 - metabolic formation of, 100
- 7-MBA DNA adducts, 118—20
 - comparison of, 118—19
 - evidence for binding via bay region diol epoxide, 119—20
 - fluorescence spectra of, 119—20
- 12-MBA DNA adducts, 122
- 1-MBA 5,6-epoxide
 - metabolic formation of, 96
 - stereoisomers of, 96
- 7-MBA 5,6-epoxide
 - and DNA binding, 119
 - carcinogenicity, 167
 - enantiomers, 98
 - metabolic formation, 98
 - mutagenicity, 149—51
- 12-MBA 5,6-epoxide
 - effect of methyl substituent on stereoisomers of, 100
 - enantiomers, 100

- 7-MBA fluoro derivatives
 - carcinogenicity, comparison, 181
 - metabolism of, 101
- 7-MBA metabolites
 - carcinogenicity, 167
 - formation, 97—8
- MBA quinones, 31
- 5-MBA quinone
 - synthesis, 36
- 9-MBA quinone
 - synthesis, 15
- 10-MBA quinone
 - synthesis, 15
- 7-MBA RNA adducts, 119
- Mercapturic acids, 88
- Metabolism, 87—112
 - and DNA binding, 116—40
 - at methyl substituted carbon atom, 96, 100
 - conformation and, 93
 - differences in, between BA and 7-fluoroBA, 99
 - induction, effect of, 87, 90, 92, 97, 105—6, 142
 - inhibition of, 93
 - introduction to, 87—90
 - of BA, 90—6
 - of disubstituted BAs, 101—11
 - of monosubstituted BAs, 96—101
 - of trisubstituted BAs, 112
 - relationship with carcinogenicity, 88—9, 99
 - species differences in, 102
 - substituents and alteration of configuration, 90, 108
 - tissue, differences in, 88, 102, 107, 131, 152
- Methoxy BA
 - syntheses of, references to, 55—6
- 1-MethoxyBA, 31
- 3-MethoxyBA
 - synthesis, 42
- 56-MethoxyBA
 - synthesis, 43
- MethoxyBA quinones, 30—1
- 2-MethoxyBA quinone
 - synthesis, 30
- 3-MethoxyBA quinone
 - synthesis, 30
- 4-MethoxyBA quinone
 - synthesis, 30
- 8-MethoxyBA quinone
 - synthesis, 30
- 11-MethoxyBA quinone
 - synthesis, 30
- 4-Methoxy-7,12-DMBA
 - carcinogenicity, lack of, 182—3
- 5-Methoxy-7,12-DMBA
 - carcinogenicity, lack of, 182—3
- 6-Methoxy-7,12-DMBA
 - synthesis, 31
- 8-Methoxy-7,12-DMBA
 - carcinogenicity, 183
 - synthesis, 7, 12
- 9-Methoxy-7,12-DMBA
 - synthesis, 12—13
- 10-Methoxy-7,12-DMBA
 - synthesis, 13
- 11-Methoxy-7,12-DMBA
 - synthesis, 7, 12
- 1-Methoxy-4-MBA quinone
 - synthesis, 32—3
- 6,8-Methoxy-3-MBA quinone
 - synthesis, 45
- 8-Methoxy-3-methylcholanthrene
 - synthesis, 14
- 9-Methoxy-3-methylcholanthrene
 - synthesis, 14
- 10-Methoxy-3-methylcholanthrene
 - synthesis, lack of, 14
- 11-Methoxy-3-methylcholanthrene
 - synthesis, lack of, 14
- 7-Methoxymethyl-12-MBA
 - carcinogenicity, 182—3
- 2-Methylanthracene
 - synthesis, 13
- Methylation of 7-MBA, biological, 98
- Methylation of 12-MBA, biological, 100—1
- 3-Methylcholanthrene
 - and receptor protein, 141—2
 - carcinogenicity, 83
 - effect of induction by, on metabolism, 92, 105—6
 - synthesis, 13
- Methyl lithium reagent, preparation of, 9
- Methyl substituents
 - effect on stereochemistry of metabolites, 90, 100, 108
 - enhancement in carcinogenicity with, 164—5, 169
 - metabolism of, 96—111
 - oxidative metabolism at substituted carbon of, 96, 100
- 4-Methyl-1,7,11,12-tetramethoxyBA
 - synthesis, 32—3

226 *Index*

- Mezerein, as an incomplete promoter, 174
- Michael reaction, 23—4, 42
- Miscellaneous BA syntheses, references to, 61—2
- Miscellaneous synthetic routes, 37—48
- Mitochondrial DNA, 117
- Molecular size and carcinogenicity, 169—72
- Monoalkyl BA
 carcinogenicity, 164—7
 syntheses of, references to, 50
- Monosubstituted BA
 carcinogenicity, 164—9
 DNA binding, 118—22
 metabolism, 96—101
 mutagenicity, 148—52
- Mouse embryo cells, 115
 BA binding to nuclear and
 mitochondrial DNA, comparison of, 117
 BA DNA adducts in, 118
 7,12-DMBA DNA adducts in, 123, 128, 131, 132—6, 138
 7,12-DMBA DNA adducts in,
 characterization of, 134
 7-MBA adducts in, 119
 12-MBA adducts in, 122
 metabolism in, 102
- Mouse epidermal cells, 102, 126, 152
- Mouse fibroblasts
 DNA binding in, 138
 malignant transformation of, 149—50, 152, 154—5
- Mouse lymphoma cells, 152
- Mouse macrophages, 103
- Mouse prostate cells, malignant
 transformation of, 151, 152
- Mouse skin
 absorption from, 172
 activation of oncogene in, 125—6
 carcinogenicity in, 160—86
 DNA adducts in, 115—6, 122—7, 131, 140
 inhibitors of carcinogenicity in, 126—7, 142, 174
 initiation in, 113—14, 161, 165—6, 177
 metabolism in, 95, 101—2
 persistence of DNA adducts in, 125
 promoters, 161—3, 165, 168, 173—4, 176—8
 proteins, binding to, 115—16, 142
 stages in cancer of, 173
- Mutagenicity, 144—59
 direct, 145—6, 151, 154
 7,12-DMBA sulphate ester, 109
 inhibition of, 146—8, 152—3
 in the absence of a bay region epoxide, 154—6
 lack of correlation with
 carcinogenicity, 152—3
 of BA, 144—5
 of BA metabolites, 145—8
 of disubstituted BAs, 152—7
 of 7,12-DMBA metabolites, 154—6
 of monosubstituted BAs, 148—51
 of trisubstituted BAs, 157—9
 reviews of, 144
 without enzymic activation, 145—6, 151, 154
- 1,4-Naphthoquinone, 31—3
- NIH 3T3 cells, 125—6
- 7-NitroBA
 carcinogenicity, 168
 metabolism, 99
 mutagenicity, 151
 synthesis, 18—19
- N⁶-(12-methylbenz[a]anthracenyl-7-methyl) deoxyadenosine, 140
- Nomenclature of BAs, 1
- Noncovalent polycyclicaromatic
 hydrocarbon DNA interactions, 116—17
- Nuclear proteins, 143
- Oncogenes, 114, 125—6, 128
- Optical activity of *trans*-dihydrodiols and
 diol epoxides, 89—90
- Optical isomers, differences in
 carcinogenicity of, 163—4, see
 also under enantiomers
- Organometallic intermediates, 9—13
- Ornithine decarboxylase, 173
- Oxidative metabolism at a substituted
 carbon, 96, 100
- OxoBAs
 carcinogenicity, 169
 mutagenicity, 151
- Oxygen, addition to BA and derivatives, 20
- Parenchymal cells, 111, 142
- 1,4-Phenanthraquinones, 30
- Phenobarbital induction, 92, 105—6
- 2-PhenylBA
 synthesis, 46, 52

- 7-PhenylBA
 carcinogenicity, 166
 synthesis, 6, 14, 52
- 9-PhenylBA
 synthesis, 13
- 12-PhenylBA
 synthesis, 14, 52
- Phenylboronic acid, 133—4
- Photoactivation, 141—2
- Photochemical cyclization, 34—6
- Photocycloaddition, difficulties with, 36
- Phthalaldehyde acid, 11
- Physiological state and metabolism, 110—11
- Plant flavanoids, 146—8
- 7,12-Pleiadenediones, 17—18
- Polycyclic aromatic hydrocarbons
 activation not involving bay region diol epoxide, 154—6
 activation with bay region diol epoxide, 85, 162—4
 dihydrodiols, correlation of mutagenic and carcinogenic activity, 146
 DNA binding, 140, 153
 DNA binding and carcinogenicity, 129—30, 153
- ³²P-postlabelling, 124—5
- Pregnenolone, conversion into 4,7-DMBA, 43—4
- Pregnancy and reduction in mammary cancer, 175
- Progesterone, 142
- Progesterone receptor, enhanced binding of, 142—3
- Promotion, 85, 143
 by application to skin, 161—74
 by application using tampons, 174
 discussion of, 173—4
 possible mechanism of, 125, 168
- Proteins, binding to, 141—3
- Purification of BAs, 1
- Rat
 liver, use of in the formation of DNA adducts, 115, 131
 liver cytosol, hydroxylation by, 105
 liver cytosol, methylation by, 95—6, 98
 liver, metabolism by 91—101, 103—9
 liver induction, effect on metabolism, 97, 105—6
 mammary cells, comparison of mutagenic species from different carcinogens, 157
 Receptor protein, and cytochrome P-450 induction, 141—2
- References
 to Part 1 (chemistry), 63—81
 to Part 2 (biology), 187—210
- Reformatsky reaction, 22—3
- 12-Retinoylphorbol-13-acetate, 174
- Reviews of biological activity of BA and derivatives, 85
- RNA, 114—41
- Robinson-Mannich synthesis, 23—4
- Salmonella typhimurium*, mutagenicity of BA, comparison of different strains, 144—5
 of BA halogen derivatives in, 151
 of BA metabolites in, 145—6, 151
 of 7,12-DMBA in, 152
 of 7,12-DMBA metabolites in, 109, 154, 156
 of 6-MBA metabolites in, 149
 of 7-MBA metabolites in, 149
- Seaweed, inhibition of mutagenicity by, 152
- Sephadex LH20, 118—20, 122—3
- Skin carcinogenesis, see also mouse skin by 7,12-DMBA and derivatives, 172—4, 177—80
 inhibition of, 174
 initiation of, 177
- Somatic mutation theory, 113
- Soot, 145
- Specific protein binding by 7,12-DMBA, 143
- Spiro compounds, effect of steric hinderance, 22
- Sprague Dawley rat, 129, 157
- Stages in cancer, 173
- 7-StearoylBA
 synthesis, 20
- Stereochemistry of BA derivatives, 89, 93, 97—8, 100
- Steric hinderance, and conformation, 89
 and metabolism, 90, 93—4, 107
- Steroids
 conversion into polycyclic aromatic hydrocarbons, 43—4
 effect of 7,12-DMBA on protein binding of, 143

228 *Index*

- effect on adrenal necrosis, 180
- Stobbe condensation, 38—9
- Stromal cells, 111
- Styrenes, use of in synthesis, 31
- 7-Substituted BAs, metabolism 97—9
- Sulphate conjugates, 88, 90
- 7-SulphydrylBA
synthesis, 18—19
- Superoxide dismutase, 152
- Syrian hamster embryo cells, malignant transformation of, 145
- Tampons, use of in promotion, 174
- Testes, effect of 7,12-DMBA on, 109, 180
- Tetraugulol
synthesis, 46
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin,
141—2, 174
- 12-*O*-Tetradecanoylphorbol-13-acetate, 173
- 1,2,3,4-TetrahydroBA, DNA interactions
of, 116—17
- 8,9,10,11-TetrahydroBA, DNA interactions
of, 116—17
- 1,2,3,4-TetrahydroBA quinone,
synthesis, 31
- 1,2,3,4-Tetrahydro-7,12-DMBA
carcinogenicity, 179
mutagenicity, 154—6
- TetraMBA
syntheses of, references to, 52
- 7,8,9,12-TetraMBA
carcinogenicity, 186
synthesis, 6
- Tetrasubstituted BAs, carcinogenicity, 186
- Tetrol, from diol epoxide, 88
- Thiol containing BAs, carcinogenicity,
169
- Transplacental carcinogenicity, 176
- Trialkyl BA
carcinogenicity, 183—5
syntheses of, references to, 52
- 1,1,1-Trichloropropene-2,3-oxide, 133
- 9-Trifluoromethyl-7,12-DMBA
carcinogenicity, 185
synthesis, 13
- 10-Trifluoromethyl-7,12-DMBA
carcinogenicity, 185
synthesis, 13
- TriMBA
carcinogenicity, comparison of, 183—
5
syntheses of, references to, 52
- 1,7,12-TriMBA
carcinogenicity, 183—5
synthesis, 33
- 2,7,12-TriMBA
carcinogenicity, 183—5
synthesis, difficulties in, 6
- 3,7,12-TriMBA
carcinogenicity, 183—5
- 4,7,12-TriMBA
carcinogenicity, 183—5
- 5,7,12-TriMBA
carcinogenicity, 183—5
- 6,7,8-TriMBA
carcinogenicity, 183—5
synthesis, 9
- 6,7,12-TriMBA
carcinogenicity, 183—5
- 6,8,11-TriMBA
synthesis, 40—1
- 6,8,12-TriMBA
carcinogenicity, 183—5
- 7,8,12-TriMBA
carcinogenicity, 183—5
- 7,9,12-TriMBA
carcinogenicity, 183—5
- 7,10,12-TriMBA
carcinogenicity, 183—5
- 7,11,12-TriMBA
carcinogenicity, 183—5
synthesis, 6
- 8,9,11-TriMBA
synthesis, 29—30
- Trisubstituted BAs
carcinogenicity, 183—5
DNA binding, 140—1
metabolism, 112
mutagenicity, 157—9
- Tumour progression, model for, 168
- Urine metabolite, 85
- Vilsmeier reaction, 42
- Vinyl cyclohexanes, use of in synthesis,
31
- Vinylene carbonate, use of in synthesis,
11
- Wagner-Meerwein rearrangement, 43—4
- Wistar-Furth rat, 157
- Wittig reaction, 42
- X-ray crystallography, 140
- Zona fasciculata, 109
- Zona reticularis, 109